Small Molecule Screening Identifies HSP90 as a Modifier of RNA Foci in Myotonic Dystrophy Type 1
- 17 October 2024
- journal article
- research article
- Published by Taylor & Francis in Molecular and Cellular Biology
- Vol. 45 (6) , 225-237
Abstract
Myotonic dystrophy type 1 (DM1) is a multisystemic disorder caused by a CTG triplet repeat expansion within the 3' untranslated region of the DMPK gene. Expression of the expanded allele generates RNA containing long tracts of CUG repeats (CUGexp RNA) that form hairpin structures and accumulate in nuclear RNA foci; however, the factors that control DMPK expression and the formation of CUGexp RNA foci remain largely unknown. We performed an unbiased small molecule screen in an immortalized human DM1 skeletal muscle myoblast cell line and identified HSP90 as a modifier of endogenous RNA foci. Small molecule inhibition of HSP90 leads to enhancement of RNA foci and upregulation of DMPK mRNA levels. Knockdown and overexpression of HSP90 in undifferentiated DM1 myoblasts validated the impact of HSP90 with upregulation and downregulation of DMPK mRNA, respectively. Furthermore, we identified p-STAT3 as a downstream mediator of HSP90 impacting levels of DMPK mRNA and RNA foci. Interestingly, differentiated cells exhibited an opposite effect of HSP90 inhibition displaying downregulation of DMPK mRNA through a mechanism independent of p-STAT3 involvement. This study has revealed a novel mediator for DMPK mRNA and foci regulation in DM1 cells with the potential to identify targets for future therapeutic intervention.Keywords
Funding Information
- National Institutes of Health (RP150578, RP200668)
- CPRIT (RP150578, RP200668)
This publication has 61 references indexed in Scilit:
- An update on the status of HSP90 inhibitors in cancer clinical trialsCell Stress and Chaperones, 2024
- Molecular-level interplay between intrinsically disordered clients and Hsp90Current Opinion in Chemical Biology, 2023
- The disruption of protein−protein interactions with co-chaperones and client substrates as a strategy towards Hsp90 inhibitionActa Pharmaceutica Sinica B, 2021
- Myotonic dystrophy: candidate small molecule therapeuticsDrug Discovery Today, 2017
- Splicing biomarkers of disease severity in myotonic dystrophyAnnals of Neurology, 2013
- Hsp90 Globally Targets Paused RNA Polymerase to Regulate Gene Expression in Response to Environmental StimuliCell, 2012
- STAT3 interacts directly with Hsp90IUBMB Life, 2012
- Hsp90 and Client Protein Maturation2011
- Pharmacological inhibition of HSP90 activity negatively modulates myogenic differentiation and cell survival in C2C12 cellsMolecular and Cellular Biochemistry, 2011
- Molecular basis of myotonic dystrophy: Expansion of a trinucleotide (CTG) repeat at the 3′ end of a transcript encoding a protein kinase family memberCell, 1992